Bilirubin-induced neurologic damage - Mechanisms and management approaches

New England Journal of Medicine

Volumn 369, Issue 21, 2013, Pages 2021-2030

  Watchko, Jon F ^a   Tiribelli, Claudio ^b,c  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b Centro Studi Fegato   (Italy)

^c UNIVERSITY OF TRIESTE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BILIRUBIN; IMMUNOGLOBULIN; MESOPORPHYRIN; METALLOPORPHYRIN; MINOCYCLINE; MULTIDRUG RESISTANCE PROTEIN 1; PHENOBARBITAL;

ASTROCYTE CULTURE; BILIRUBIN BLOOD LEVEL; BLOOD BRAIN BARRIER; BLOOD CEREBROSPINAL FLUID BARRIER; BRAIN DAMAGE; BRAIN REGION; CELL SPECIFICITY; CEREBELLUM HYPOPLASIA; CLINICAL FEATURE; DISEASE ACTIVITY; DRUG MECHANISM; EXCHANGE BLOOD TRANSFUSION; EXPERIMENTAL ANIMAL; HUMAN; HYPERBILIRUBINEMIA; KERNICTERUS; MICROGLIA; NEUROPATHOLOGY; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; OLIGODENDROGLIA; PHOTOTHERAPY; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW;

EID: 84889805741     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMra1308124     Document Type: Review

References (78)

1. Shapiro SM. Kernicterus. In: Stevenson DK, Maisels MJ, Watchko JF, eds. Care of the jaundiced neonate. New York: McGraw-Hill, 2012:229-42.
2. Watchko JF. Kernicterus and the molecular mechanisms of bilirubin-induced CNS injury in newborns. Neuromolecular Med 2006;8:513-29.
3. Ahdab-Barmada M. The neuropathology of kernicterus: definition and debate. In: Maisels MJ, Watchko JF, eds. Neonatal jaundice. Newark, NJ: Harwood Academic, 2000:75-88.
4. Bhutani VK, Johnson LH, Jeffrey Maisels M, et al. Kernicterus: epidemiological strategies for its prevention through systems-based approaches. J Perinatol 2004;24:650-62.
5. Johnson L, Bhutani VK, Karp K, Sivieri EM, Shapiro SM. Clinical report from the pilot USA Kernicterus Registry (1992 to 2004). J Perinatol 2009;29:Suppl 1:S25S-S45.
6. Manning D, Todd P, Maxwell M, Platt MJ. Prospective surveillance study of severe hyperbilirubinaemia in the newborn in the UK and Ireland. Arch Dis Child Fetal Neonatal Ed 2007;92:F342-F346.
7. Sgro M, Campbell DM, Kandasamy S, Shah V. Incidence of chronic bilirubin encephalopathy in Canada, 2007-2008. Pediatrics 2012;130(4):e886-e990.
8. Slusher TM, Olusaniya BO. Neonatal jaundice in low-and middle-income countries. In: Stevenson DK, Maisels MJ, Watchko JF, eds. Care of the jaundiced neonate. New York: McGraw-Hill, 2012:263-73.
9. Maisels MJ, Newman TB. Prevention, screening and postnatal management of neonatal hyperbilirubinemia. In: Stevenson DK, Maisels MJ, Watchko JF, eds. Care of the jaundiced neonate. New York: McGraw-Hill, 2012:175-94.
10. Ogunlesi TA, Dedeke IO, Adekanmbi AF, et al. The incidence and outcome of bilirubin encephalopathy in Nigeria: a bicentre study. Niger J Med 2007;16:354-9.
11. Jamison DT, Breman JC, Measham AR, et al. Disease control priorities in developing countries. 2nd ed. Washington, DC: World Bank and Oxford University Press, 2006.
12. Nkhoma ET, Poole C, Vannappagari V, Hall SA, Beutler E. The global prevalence of glucose-6-phosphate dehydrogenase deficiency: a systematic review and meta-analysis. Blood Cells Mol Dis 2009;42:267-78.
13. Zipursky A, Paul VK. The global burden of Rh disease. Arch Dis Child Fetal Neonatal Ed 2011;96:F84-F85.
14. Gamaleldin R, Iskander I, Seoud I, et al. Risk factors for neurotoxicity in newborns with severe neonatal hyperbilirubinemia. Pediatrics 2011;128(4):e925-e931.
15. Coda Zabetta CD, Iskander IF, Greco C, et al. Bilistick: a low-cost point-of-care system to measure total plasma bilirubin. Neonatology 2013;103:177-81.
16. Brites D, Brito MA. Bilirubin toxicity. In: Stevenson DK, Maisels MJ, Watchko JF, eds. Care of the jaundiced neonate. New York: McGraw-Hill, 2012:115-43.
17. Ip S, Chung M, Kulig J, et al. An evidence-based review of important issues concerning neonatal hyperbilirubinemia. Pediatrics 2004;114(1):e130-e153.
18. Ahlfors CE, Wennberg RP, Ostrow JD, Tiribelli C. Unbound (free) bilirubin: improving the paradigm for evaluating neonatal jaundice. Clin Chem 2009;55:1288-99.
19. Ahlfors CE. Predicting bilirubin neurotoxicity in jaundiced newborns. Curr Opin Pediatr 2010;22:129-33.
20. Newman TB, Liljestrand P, Jeremy RJ, et al. Outcomes among newborns with total serum bilirubin levels of 25 mg per deciliter or more. N Engl J Med 2006;354:1889-900.
21. Oh W, Stevenson DK, Tyson JE, et al. Influence of clinical status on the association between plasma total and unbound bilirubin and death or adverse neurodevelopmental outcomes in extremely low birth weight infants. Acta Paediatr 2010;99:673-8. [Erratum, Acta Paediatr 2013;102:326.]
22. Ahlfors CE, Parker AE. Bilirubin binding contributes to the increase in total bilirubin concentration in newborns with jaundice. Pediatrics 2010;126(3):e639-e643.
23. Ahlfors CE. Criteria for exchange transfusion in jaundiced newborns. Pediatrics 1994;93:488-94.
24. Cashore WJ, Oh W, Brodersen R. Reserve albumin and bilirubin toxicity index in infant serum. Acta Paediatr Scand 1983;72:415-9.
25. Wennberg RP, Ahlfors CE, Bhutani VK, Johnson LH, Shapiro SM. Toward understanding kernicterus: a challenge to improve the management of jaundiced newborns. Pediatrics 2006;117:474-85. [Erratum, Pediatrics 2006;117:1467.]
26. Wennberg RP. Measuring free bilirubin: the clinical perspective. Clin Chem 2012;58:811-3.
27. McDonagh AF, Maisels MJ. Bilirubin unbound: déjà vu all over again? Pediatrics 2006;117:523-5.
28. Weisiger RA, Ostrow JD, Koehler RK, et al. Affinity of human serum albumin for bilirubin varies with albumin concentration and buffer composition: results of a novel ultrafiltration method. J Biol Chem 2001;276:29953-60.
29. Roca L, Calligaris S, Wennberg RP, et al. Factors affecting the binding of bilirubin to serum albumins: validation and application of the peroxidase method. Pediatr Res 2006;60:724-8.
30. Lasky RE, Church MW, Orlando MS, et al. The effects of aggressive vs. conservative phototherapy on the brainstem auditory evoked responses of extremely-low-birth-weight infants. Pediatr Res 2012;71:77-84.
31. Daood MJ, Watchko JF. Calculated in vivo free bilirubin levels in the central nervous system of Gunn rat pups. Pediatr Res 2006;60:44-9.
32. Daood MJ, McDonagh AF, Watchko JF. Calculated free bilirubin levels and neurotoxicity. J Perinatol 2009;29:Suppl 1:S14-S19.
33. Gazzin S, Zelenka J, Zdrahalova L, et al. Bilirubin accumulation and Cyp mRNA expression in selected brain regions of jaundiced Gunn rat pups. Pediatr Res 2012;71:653-60. [Erratum, Pediatr Res 2012;71:732.]
34. Gazzin S, Strazielle N, Tiribelli C, Ghersi-Egea JF. Transport and metabolism at blood-brain interfaces and in neural cells: relevance to bilirubin-induced encephalopathy. Front Pharmacol 2012;3:89.
35. Ghersi-Egea JF, Gazzin S, Strazielle N. Blood-brain interfaces and bilirubin-induced neurological diseases. Curr Pharm Des 2009;15:2893-907.
36. Ostrow JD, Pascolo L, Tiribelli C. Reassessment of the unbound concentrations of unconjugated bilirubin in relation to neurotoxicity in vitro. Pediatr Res 2003;54:926.
37. Ostrow JD, Pascolo L, Brites D, Tiribelli C. Molecular basis of bilirubin-induced neurotoxicity. Trends Mol Med 2004;10:65-70.
38. Morris BH, Oh W, Tyson JE, et al. Aggressive vs. conservative phototherapy for infants with extremely low birth weight. N Engl J Med 2008;359:1885-96.
39. Bender GJ, Cashore WJ, Oh W. Ontogeny of bilirubin-binding capacity and the effect of clinical status in premature infants born at less than 1300 grams. Pediatrics 2007;120:1067-73.
40. Mreihil K, McDonagh AF, Nakstad B, Hansen TW. Early isomerization of bilirubin in phototherapy of neonatal jaundice. Pediatr Res 2010;67:656-9.
41. McDonagh AF, Vreman HJ, Wong RJ, Stevenson DK. Photoisomers: obfuscating factors in clinical peroxidase measurements of unbound bilirubin? Pediatrics 2009;123:67-76.
42. American Academy of Pediatrics Subcommittee on Hyperbilirubinemia. Management of hyperbilirubinemia in the newborn infant 35 or more weeks of gestation. Pediatrics 2004;114:297-316. [Erratum, Pediatrics 2004;114:1138.]
43. Vader-van Imhoff DE. BARTrial: the management of hyperbilirubinemia in preterm infants. Amsterdam: Netherlands Neonatal Research Network (http://www.neonatologiestudies.nl/home/page.asp?page-id=1076).
44. Zucker SD, Goessling W, Hoppin AG. Unconjugated bilirubin exhibits spontaneous diffusion through model lipid bilayers and native hepatocyte membranes. J Biol Chem 1999;274:10852-62.
45. Vítek L, Ostrow JD. Bilirubin chemistry and metabolism; harmful and protective aspects. Curr Pharm Des 2009;15:2869-83.
46. Gazzin S, Strazielle N, Schmitt C, et al. Differential expression of the multidrug resistance-related proteins ABCb1 and ABCc1 between blood-brain interfaces. J Comp Neurol 2008;510:497-507.
47. Daood M, Tsai C, Ahdab-Barmada M, Watchko JF. ABC transporter (P-gp/ABCB1, MRP1/ABCC1, BCRP/ABCG2) expression in the developing human CNS. Neuropediatrics 2008;39:211-8.
48. Corich L, Aranda A, Carrassa L, Bellarosa C, Ostrow JD, Tiribelli C. The cytotoxic effect of unconjugated bilirubin in human neuroblastoma SH-SY5Y cells is modulated by the expression level of MRP1 but not MDR1. Biochem J 2009;417:305-12.
49. Gazzin S, Berengeno AL, Strazielle N, et al. Modulation of Mrp1 (ABCc1) and Pgp (ABCb1) by bilirubin at the blood-CSF and blood-brain barriers in the Gunn rat. PLoS One 2011;6(1):e16165.
50. Kapitulnik J, Gonzalez FJ. Marked endogenous activation of the CYP1A1 and CYP1A2 genes in the congenitally jaundiced Gunn rat. Mol Pharmacol 1993;43:722-5.
51. Kapitulnik J, Hardwick JP, Ostrow JD, Webster CC, Park SS, Gelboin HV. Increase in a specific cytochrome P-450 isoenzyme in the liver of congenitally jaundiced Gunn rats. Biochem J 1987;242:297-300.
52. Abu-Bakar A, Moore MR, Lang MA. Evidence for induced microsomal bilirubin degradation by cytochrome P450 2A5. Biochem Pharmacol 2005;70:1527-35.
53. Brito MA, Lima S, Fernandes A, et al. Bilirubin injury to neurons: contribution of oxidative stress and rescue by glycoursodeoxycholic acid. Neurotoxicology 2008;29:259-69.
54. Vaz AR, Delgado-Esteban M, Brito MA, Bolaños JP, Brites D, Almeida A. Bilirubin selectively inhibits cytochrome c oxidase activity and induces apoptosis in immature cortical neurons: assessment of the protective effects of glycoursodeoxycholic acid. J Neurochem 2010;112:56-65.
55. Rodrigues CM, Solá S, Brites D. Bilirubin induces apoptosis via the mitochondrial pathway in developing rat brain neurons. Hepatology 2002;35:1186-95.
56. Fernandes A, Falcão AS, Abranches E, et al. Bilirubin as a determinant for altered neurogenesis, neuritogenesis, and synaptogenesis. Dev Neurobiol 2009;69:568-82.
57. Brites D. Bilirubin injury to neurons and glial cells: new players, novel targets, and newer insights. Semin Perinatol 2011;35:114-20.
58. Silva SL, Vaz AR, Barateiro A, et al. Features of bilirubin-induced reactive microglia: from phagocytosis to inflammation. Neurobiol Dis 2010;40:663-75.
59. Deganuto M, Cesaratto L, Bellarosa C, et al. A proteomic approach to the bilirubin-induced toxicity in neuronal cells reveals a protective function of DJ-1 protein. Proteomics 2010;10:1645-57.
60. Falcão AS, Silva RF, Pancadas S, Fernandes A, Brito MA, Brites D. Apoptosis and impairment of neurite network by short exposure of immature rat cortical neurons to unconjugated bilirubin increase with cell differentiation and are additionally enhanced by an inflammatory stimulus. J Neurosci Res 2007;85:1229-39.
61. Ollinger R, Kogler P, Troppmair J, et al. Bilirubin inhibits tumor cell growth via activation of ERK. Cell Cycle 2007;6:3078-85.
62. Ollinger R, Yamashita K, Bilban M, et al. Bilirubin and biliverdin treatment of atherosclerotic diseases. Cell Cycle 2007;6:39-43.
63. Brito MA, Vaz AR, Silva SL, et al. N-methyl-aspartate receptor and neuronal nitric oxide synthase activation mediate bilirubin-induced neurotoxicity. Mol Med 2010;16:372-80.
64. Giraudi PJ, Bellarosa C, Coda-Zabetta CD, Peruzzo P, Tiribelli C. Functional induction of the cystine-glutamate exchanger system Xc(-) activity in SH-SY5Y cells by unconjugated bilirubin. PLoS One 2011;6(12):e29078.
65. Gennuso F, Fernetti C, Tirolo C, et al. Bilirubin protects astrocytes from its own toxicity by inducing up-regulation and translocation of multidrug resistance-associated protein 1 (Mrp1). Proc Natl Acad Sci U S A 2004;101:2470-5.
66. Brites D. The evolving landscape of neurotoxicity by unconjugated bilirubin: role of glial cells and inflammation. Front Pharmacol 2012;3:88.
67. Shapiro SM. Chronic bilirubin encephalopathy: diagnosis and outcome. Semin Fetal Neonatal Med 2010;15:157-63.
68. Palmela I, Sasaki H, Cardoso FL, et al. Time-dependent dual effects of high levels of unconjugated bilirubin on the human blood-brain barrier lining. Front Cell Neurosci 2012;6:22.
69. Falcão AS, Silva RF, Vaz AR, Silva SL, Fernandes A, Brites D. Cross-talk between neurons and astrocytes in response to bilirubin: early beneficial effects. Neurochem Res 2013;38:644-59.
70. Daood MJ, Hoyson M, Watchko JF. Lipid peroxidation is not the primary mechanism of bilirubin-induced neurologic dysfunction in jaundiced Gunn rat pups. Pediatr Res 2012;72:455-9.
71. Chowdhury JR, Kondapalli R, Chowdhury NR. Gunn rat: a model for inherited deficiency of bilirubin glucuronidation. Adv Vet Sci Comp Med 1993;37:149-73.
72. Gunn CH. Hereditary acholuric jaundice in a new mutant strain of rats. J Hered 1938;29:137-9.
73. Bortolussi G, Zentilin L, Baj G, et al. Rescue of bilirubin-induced neonatal lethality in a mouse model of Crigler-Najjar syndrome type I by AAV9-mediated gene transfer. FASEB J 2012;26:1052-63.
74. Maisels MJ, Stevenson D, Watchko JF, McDonagh AF. Phototherapy and other treatments. In: Stevenson DK, Maisels MJ, Watchko JF, eds. Care of the jaundiced neonate. New York: McGraw-Hill, 2012:195-227.
75. Hansen TW, Nietsch L, Norman E, et al. Reversibility of acute intermediate phase bilirubin encephalopathy. Acta Paediatr 2009;98:1689-94.
76. Schulz S, Wong RJ, Vreman HJ, Stevenson DK. Metalloporphyrins - an update. Front Pharmacol 2012;3:68.
77. Lin S, Wei X, Bales KR, et al. Minocycline blocks bilirubin neurotoxicity and prevents hyperbilirubinemia-induced cerebellar hypoplasia in the Gunn rat. Eur J Neurosci 2005;22:21-7.
78. Geiger AS, Rice AC, Shapiro SM. Minocycline blocks acute bilirubin-induced neurological dysfunction in jaundiced Gunn rats. Neonatology 2007;92:219-26.